Dr. Zhu on Optimal Second-Line Treatment for Patients With HCC

Andrew X. Zhu, MD
Published: Friday, Sep 09, 2016



Andrew X. Zhu, MD, PhD, professor of Medicine, Harvard Medical School, director of Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the possibility of an optimal second-line treatment for all patients with hepatocellular carcinoma (HCC).

Choosing a second-line treatment in an unselected group of patients is increasing the risk for failure, Zhu explains. However, since researchers do not yet know the true mechanism of action for certain agents, such as regorafenib (Stivarga), it's difficult to determine which subgroup of patients they will demonstrate the most promise in—although regorafenib is associated with an improvement in overall survival.

There are also early, encouraging results with single-agent nivolumab (Opdivo) in HCC, with an approximate 60% response rate in all-comers; however, there is no biomarker yet to determine which patients will benefit most.

This poses a challenge not just in second-line, but across all patients in the frontline setting, Zhu says.

<<< View more from the 2016 International Liver Cancer Association Annual Conference



Andrew X. Zhu, MD, PhD, professor of Medicine, Harvard Medical School, director of Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the possibility of an optimal second-line treatment for all patients with hepatocellular carcinoma (HCC).

Choosing a second-line treatment in an unselected group of patients is increasing the risk for failure, Zhu explains. However, since researchers do not yet know the true mechanism of action for certain agents, such as regorafenib (Stivarga), it's difficult to determine which subgroup of patients they will demonstrate the most promise in—although regorafenib is associated with an improvement in overall survival.

There are also early, encouraging results with single-agent nivolumab (Opdivo) in HCC, with an approximate 60% response rate in all-comers; however, there is no biomarker yet to determine which patients will benefit most.

This poses a challenge not just in second-line, but across all patients in the frontline setting, Zhu says.

<<< View more from the 2016 International Liver Cancer Association Annual Conference


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x